<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="da5652f8-585c-4697-bc65-2a613cb0ef0f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">TRIAMCINOLONE ACETONIDE DENTAL PASTE, USP 0.1%   </content>
      <br/>
      <br/>
      <br/>
      <br/>
      <content styleCode="bold"> Rx only   </content>
   </title>
   <effectiveTime value="20250320"/>
   <setId root="da5652f8-585c-4697-bc65-2a613cb0ef0f"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
            <name>Preferred Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                  <name>Preferred Pharmaceuticals Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                        <name>Preferred Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68788-8841" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="0c93b789-9e40-4ce2-809d-0f75a0eced28"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="68788-8841"/>
                        <name>Triamcinolone Acetonide</name>
                        <formCode code="C42967" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PASTE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Triamcinolone Acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0713-0655" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="89NA02M4RX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PECTIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UG00KM4WR7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HIGH DENSITY POLYETHYLENE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F446C597KA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIAMCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="F446C597KA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIAMCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68788-8841-5" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250320"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA205592" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250320"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>light beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38197" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="DENTAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_e5e381bb-62f4-4ac6-9ec1-61892917b592">
               <id root="06897db7-0a02-4ce6-bfcf-8b644d69bdb3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Triamcinolone Acetonide Dental Paste, USP 0.1%, contains the corticosteroid triamcinolone acetonide in an adhesive vehicle suitable for application to oral tissues. Triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The structural formula of triamcinolone acetonide is as follows:</paragraph>
                  <renderMultiMedia referencedObject="FD2470FD-2723-43D3-A3A7-9444B658FAC2" ID="id256"/>
                  <paragraph>Each gram of triamcinolone acetonide dental paste contains 1 mg triamcinolone acetonide in an emollient dental paste containing gelatin, pectin, and carboxymethylcellulose sodium in a plasticized hydrocarbon gel (a polyethylene and mineral oil gel base).</paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="FD2470FD-2723-43D3-A3A7-9444B658FAC2">
                     <text>Triamcinolone Acetonide Dental Paste-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Triamcinolone Acetonide Dental Paste-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bb7a176b-afa8-4630-b8f9-8de758b37f0f">
               <id root="b5fcfdb1-6d4d-4ab1-85ed-694a7a148a74"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Like other topical corticosteroids, triamcinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A             <sub>2</sub> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A             <sub>2</sub>.          </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="ID_6e2d26e1-293b-46bd-9bd2-a19392b15a03">
                     <id root="548b1d8f-9fec-4fc8-bbf2-c7d17c074607"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>The extent of absorption through the oral mucosa is determined by multiple factors including the vehicle, the integrity of the mucosal barrier, the duration of therapy, and the presence of inflammation and/or other disease processes. Once absorbed through the mucous membranes, the disposition of corticosteroids is similar to that of systemically administered corticosteroids. Corticosteroids are bound to the plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys; some corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a71a4ee4-ba4d-4f12-afcf-1c6768093db6">
               <id root="252f09f7-e465-44a7-b231-9866cef49bf4"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Triamcinolone Acetonide Dental Paste, USP 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="ID_8eae11dd-52b9-45a5-bb43-b4aa85defdcc">
               <id root="2c865af4-7901-45af-b7ff-453fdd67b0af"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Triamcinolone acetonide dental paste is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="pre">
               <id root="af4b0f21-9ffb-41dc-a4c7-ac076e4ad9ec"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42232-9" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="ID_aa41debd-48a2-4b45-9a60-c8852b80006a">
                     <id root="c21695dd-07bc-4906-a067-3b803c6ba918"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34072-9" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Triamcinolone acetonide dental paste may cause local adverse reactions. If irritation develops, triamcinolone acetonide dental paste should be discontinued and appropriate therapy instituted. Allergic contact sensitization with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.</content>
                        </paragraph>
                        <paragraph>If concomitant mucosal infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of triamcinolone acetonide dental paste should be discontinued until the infection has been adequately controlled.</paragraph>
                        <paragraph>If significant regeneration or repair of oral tissues has not occurred in seven days, additional investigation into the etiology of the oral lesion is advised.</paragraph>
                        <paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, glucosuria, and other adverse effects known to occur with parenterally-administered steroid preparations; therefore, it may be advisable to periodically evaluate patients on prolonged therapy with corticosteroid-containing dental pastes for evidence of HPA axis suppression (see                <content styleCode="bold">
                              <linkHtml href="#labtest">PRECAUTIONS, Laboratory Tests</linkHtml>
                           </content>). If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. Recovery of HPA axis function is generally prompt and complete upon discontinuation of therapy.            </paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_161825c1-406b-49f4-8bc4-529628091427">
                     <id root="30744b83-47ec-49f9-ac8a-1f586ca85715"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>This medication is to be used as directed by the physician or dentist. It is for oral use only; it is not intended for ophthalmic or dermatological use.  </item>
                           <item>
                              <caption>2.</caption>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.  </item>
                           <item>
                              <caption>3.</caption>Patients should report any signs of adverse reactions.  </item>
                           <item>
                              <caption>4.</caption>As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician or dentist. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="labtest">
                     <id root="167ddf35-ce22-4380-aa5e-4b38fa01006c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34075-2" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_988e5fc4-df79-49fd-bd1e-ce0c9825dd33">
                     <id root="c77eae82-560e-4695-85a4-6712da28f80a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate triamcinolone acetonide for potential to induce carcinogenesis, mutagenesis, or impairment of fertility.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3cdaa37-8962-4dcb-9298-bae01aa62e77">
                     <id root="a10b0798-c8cb-4a26-aaac-07c70ced7a4c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy Category C</title>
                     <effectiveTime value="20250320"/>
                     <component>
                        <section ID="ID_e6177874-7aeb-4d72-a4bc-65c3ab4e6ba8">
                           <id root="6170758b-df84-4ecf-ad2d-a00bdc3ad9a7"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="34077-8" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic effects</content>
                           </title>
                           <text>
                              <paragraph>Triamcinolone acetonide has been shown to induce teratogenic effects in several species. In mice and rabbits, triamcinolone acetonide induced an increased incidence of cleft palate at dosages of approximately 120 mcg/kg/day and 24 mcg/kg/day, respectively (approximately 12 times and 10 times the amount in a typical daily human dose of triamcinolone acetonide dental paste when compared following normalization of the data on the basis of body surface area estimates, respectively). In monkeys, triamcinolone acetonide induced cranial skeletal malformations at the lowest dosage studied (500 mcg/kg/day),which was approximately 200 times the amount in a typical daily human dose of triamcinolone acetonide dental paste when compared following normalization of the data on the basis of body surface area estimates. There are no adequate and well-controlled studies in pregnant women. However, a retrospective analysis of birth defects among children born to mothers that used drugs of the same class as triamcinolone acetonide dental paste (corticosteroids) during pregnancy found an approximately 3 times increased incidence of cleft palate. Triamcinolone acetonide dental paste should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20250320"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_d6a129a7-071d-4264-82ec-71a1bc6c142d">
                     <id root="0061ba1b-8d15-4212-b770-e09d196309ea"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether oral application of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Caution should be exercised when corticosteroid-containing dental pastes are prescribed for a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c245d8ca-22ac-4a97-b931-0b952d62dbac">
                     <id root="9cbbf08c-2bc9-4d19-a309-817816ffdeb1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of triamcinolone acetonide dental paste in children is unknown. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's Syndrome than mature patients because of a larger skin surface area to body weight ratio. Administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ed587c46-68a2-4ccd-9cc0-fe3f95770e19">
                     <id root="746c954a-5a23-4094-a769-7199deea9d2f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of triamcinolone acetonide dental paste did not include sufficient numbers of subjects age 65 and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_63867df6-cfa0-45b7-a36b-1c58341462fb">
               <id root="ce62dbe8-8bd3-4f44-9db5-dad3be63a86c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa.              <br/>
                     <br/>Also, see              <content styleCode="bold">
                        <linkHtml href="#pre">PRECAUTIONS</linkHtml>
                     </content>for potential effects of systemic absorption.             <br/>
                     <br/>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                        <content styleCode="italics">.</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="ID_dda2a423-c81b-449c-abbe-67522e9c97f6">
               <id root="3ce5d2c6-ba49-4d0b-bd66-edfcf3c62899"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Press a small dab (about ¼ inch) to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops.</paragraph>
                  <paragraph>The preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. If significant repair or regeneration has not occurred in seven days, further investigation is advisable.</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="ID_2c1de7cb-d8bd-446d-b8c4-dae2e8d2c7e6">
               <id root="52b109c6-29e6-479a-8603-83546e476061"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Triamcinolone Acetonide Dental Paste, USP 0.1% is supplied in tubes containing 5 g of dental paste <content styleCode="bold">NDC 68788-8841-5</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <section ID="ID_0767951e-f825-4a2b-83e3-d0fe17b30056">
                     <id root="362bf2a7-f1c5-4663-9027-85059a116d79"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="44425-7" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>Storage</title>
                     <text>
                        <paragraph>Keep tightly closed.                <content styleCode="bold">Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distributed by:</content>
                           <br/>Cosette Pharmaceuticals, Inc.               <br/>South Plainfield, NJ 07080            </paragraph>
                        <paragraph>
                           <content styleCode="bold">Relabeled By: Preferred Pharmaceuticals Inc.</content>
                        </paragraph>
                        <paragraph>Iss. 02/2021  8-0655CPLNC1   VC7479</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_952da43f-6fcb-4b4c-b02c-8df5cd2c9723">
               <id root="592be362-2926-49a3-bd2e-012d2bacdcbb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 68788-8841-5</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Triamcinolone Acetonide Dental Paste, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL USE IN ADJUNCTIVE TREATMENT OF ORAL LESIONS.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cosette Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Relabeled By: Preferred Pharmaceuticals Inc.</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="ID_9734e366-0d4f-4995-8c3a-07a47033f272" ID="id473"/>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="ID_9734e366-0d4f-4995-8c3a-07a47033f272">
                     <text>Triamcinolone Acetonide Dental Paste USP 0.1% </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Triamcinolone Acetonide Dental Paste-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>